Rigel Readies Tavalisse For Late-May Launch After FDA Approval
Executive Summary
Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.
You may also be interested in...
Rigel’s Tavalisse Hits Pothole In Label Expansion For Hemolytic Anemia
Tavalisse misses the primary endpoint in a 90-patient Phase III trial in warm autoimmune hemolytic anemia, but Rigel contends a high placebo response in Eastern Europe confounded the results.
Kronos Bio Doubles Its Cash With $155m Financing
The cancer drug developer led by former Gilead R&D head Norbert Bischofberger will start a registrational trial for its recently acquired SYK inhibitor and the first trial for its CDK9 inhibitor.
Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.